Skip to main content
Clinical Trials/NCT01911143
NCT01911143
Completed
Not Applicable

A Retrospective, Blinded Validation Study to Assess the Accuracy of a Host-response Based Diagnostics for Distinguishing Between Bacterial and Viral Etiologies in Pediatric Patients With an Acute Febrile Disease

MeMed Diagnostics Ltd.2 sites in 1 country600 target enrollmentSeptember 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Fever
Sponsor
MeMed Diagnostics Ltd.
Enrollment
600
Locations
2
Primary Endpoint
The sensitivity and specificity of the assay in differentiating between bacterial and viral etiology of patients with an acute febrile disease
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

This is a retrospective, blinded, external validation study of a novel in-vitro diagnostic (IVD) assay that will include samples that were previously collected from febrile pediatric patients. The investigated assay measures the levels of a few host-related, blood-based, bio-markers that will be integrated into a single score. Based on this score, each patient will be classified into one of three categories: (i) bacterial immune response, (ii) viral immune response, and (iii) marginal immune response. The assay prediction and the patient diagnosis will than be unveiled and compared to determine their level of concordance.

Registry
clinicaltrials.gov
Start Date
September 2013
End Date
August 2015
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • The infectious disease samples should also fulfill the following criteria:
  • The patient had a peak temperature ≥38°C (AND)
  • Symptoms initiated ≤ 7 days before sampling
  • The non-infectious disease control group will include:
  • Patients with a non-infectious disease

Exclusion Criteria

  • Another infection episode during the last 3 weeks before sampling
  • Congenital immune deficiency (CID)
  • A proven or suspected HIV-1, HBV, HCV infection
  • Active hematological malignancy
  • Current treatment with immune-suppressive or immune-modulating
  • Other illnesses that affect life expectancy and/or quality of life

Outcomes

Primary Outcomes

The sensitivity and specificity of the assay in differentiating between bacterial and viral etiology of patients with an acute febrile disease

Time Frame: 0-7 days after the initiation of symptoms

We will evaluate the assay using the accuracy measures sensitivity and specificity of differentiating between bacterial and viral etiology of pediatric patients aged 1 month to 18 years with an acute febrile disease.

Secondary Outcomes

  • The sensitivity and specificity of the assay in differentiating between infectious and non-infectious disease etiology.(0-7 days after the initiation of symptoms)

Study Sites (2)

Loading locations...

Similar Trials